You are here

Metabolic and Cardiovascular Disorders Development Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with metabolic diseases and at cardiovascular risk. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

365体育足球On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Internal Medicine Pipeline & Trials

Internal Medicine Pipeline as of January 28, 2020

  • Discovery Projects
  • Phase 1
    5
  • Phase 2
    4
  • Phase 3
    1
  • Registration
    0
  • Total10
 
Compound Name
Indication
Phase
Submission Type
Compound Type
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
OA Signs and Symptoms (FAST TRACK), Chronic Low Back Pain (FAST TRACK), Cancer Pain (Biologic) Phase 3 New Molecular Entity Biologic
PF-07285557
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Angiopoietin Like 3(ANGPTL3)
Go to clinical trial
Cardiovascular Risk Reduction, Severe Hypertriglyceridemia
Project advanced
Phase 2 New Molecular Entity Small Molecule
PF-07055341
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
ACCi and DGAT2 Combination
Go to clinical trial
Combo of PF-05221304 and PF-06865571 for Non-Alcoholic Steatohepatitis (NASH) Phase 2 New Molecular Entity Small Molecule
PF-06835919
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Ketohexokinase (KHK) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 2 New Molecular Entity Small Molecule
PF-05221304
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) with liver fibrosis (FAST TRACK) Phase 2 New Molecular Entity Small Molecule
PF-07081532
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Go to clinical trial
Diabetes Mellitus-Type 2, Obesity
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Factor Blocker
Go to clinical trial
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
PF-06882961
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Go to clinical trial
Diabetes Mellitus-Type 2, Obesity Phase 1 New Molecular Entity Small Molecule
PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 1 New Molecular Entity Small Molecule
PF-06842874
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 4,6 Inhibitor
Go to clinical trial
Pulmonary Arterial Hypertension
Project advanced
Phase 1 New Molecular Entity Small Molecule
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options